ALung Technologies brings in $2.6m

  Artificial lung-like device developer ALung Technologies has raised $2.6 million in a new round of financing, according to an SEC filing posted this week. Pittsburgh-based ALung’s Hemolung device is an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. Money in the round so far has come from 36 anonymous investors, with the company seeking another $1.4 million before closing the debt and option round, according to the SEC filing. The company has not yet stated how it intends to use funds raised in the round. Last January, ALung Technologies reported raising $10.8 million in a round of debt financing. A month earlier, the company said its Hemolung RAS extracorporeal carbon dioxide removal device was selected for use in the world’s 1st pivotal trial of ECCO2R technology used to treat patients with acute respiratory failure. The U.K.’s National Institute for Health Research will supply $3.1 million (GBP £2.1 million) in funding for the 1,120 patient Rest trial, which looks to examine the effect of protective ventilation with veno-venous lung assist devices during respiratory failure. The trial will be jointly led by Queen’s University and Belfast Health and Social Services Trust, the company said. The post ALung Technologies brings in $2.6m appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Respiratory ALung Technologies Inc. Source Type: news

Related Links:

Hospitals exist to take care of sick people, with the goal of making them better.  Hospitals employ and work with health care professionals, again who are sworn to put taking care of patients ahead of all other concerns.However, since we foundedHealth Care Renewal, we have noted striking examples of hospital leaders threatening their hospitals'fundamental mission and/or health care professionals'core values, which we dubbedmission-hostile management.  We also saw mission-hostile management affecting the broader health care industry, particularly pharmaceutical and device companies.  Most recently, the most s...
Source: Health Care Renewal - Category: Health Management Tags: hospitals imperial CEO managerialism mission-hostile management perverse incentives Source Type: blogs
In conclusion, this is the first report to show that pyroptotic cell death occurs in the aging brain and that the inflammasome can be a viable target to decrease the oxidative stress that occurs as a result of aging. Reducing Levels of Protein Manufacture Slows Measures of Aging in Nematodes https://www.fightaging.org/archives/2018/12/reducing-levels-of-protein-manufacture-slows-measures-of-aging-in-nematodes/ Researchers here demonstrate that an antibiotic slows aging in nematode worms, providing evidence for it to work through a reduction in protein synthesis. Beyond a slowing of aging, one of the con...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In this study, the transport mechanism of furosemide (FUR), which is transported by the same novel mechanism, was examined. In vitro cell permeation studies under air-interface conditions (AICs) revealed that the permeation from powders sprayed on cell monolayers was significantly higher than that under liquid-covered conditions (LCCs) from their solutions. The permeation from amorphous solid particles was faster than that from crystals. Similar results were derived from in vitro studies using an artificial membrane, with which the permeation of FUR could be examined without water. These findings clearly indicated that the...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
Heart transplantation is the definitive treatment for end-stage heart failure. A shortage of donor hearts forced transplant programs to accept older donors and longer ischemic times. Previous studies have suggested that the administration of mesenchymal stem cells (MSCs) or their conditioned medium (CM) protects the heart against ischemia/reperfusion injury (IRI). We hypothesized that the preservation of donor hearts with a CM would protect the graft from IRI after prolonged storage in 15-month-old rats and investigated mRNA-changes attributable to CM.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Pre-Clinical Science Source Type: research
Chronic lung allograft dysfunction (CLAD) affects over 50% of lung transplant recipients (LTR) by five years and remains the primary reason for graft failure 1. It has been increasingly recognized that CLAD is a heterogeneous diagnosis with variable prognosis and different phenotypes: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). Precise diagnosis of CLAD remains difficult: There are no clinically-validated biomarkers, and diagnosis can be subjective, hinging on the correct interpretation of pulmonary function tests (PFTs) coupled with exclusion of clinical confounders.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: RESEARCH CORRESPONDENCE Source Type: research
The added value of cardiopulmonary exercise testing (CPET) in the follow-up of patients with stable pulmonary arterial hypertension (PAH) remains undefined.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Chronic lung allograft dysfunction (CLAD) is a major cause of post-lung transplant mortality with limited medical treatment options. We assessed the association of montelukast treatment with pulmonary function and outcome in lung transplant recipients with progressive CLAD.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Right ventricular failure (RVF) is still associated with an increased mortality in patients with pulmonary hypertension (PH) or congenital heart disease. Transition from right ventricular dysfunction to RVF is not predictable and has not been well understood so far. Several studies in rodents and in piglets showed that impairment of capillary density (CD) in the right ventricle (RV) is associated with right ventricular failure (1, 2). Some evidence suggested that the RV of patients with Eisenmenger Syndrome (ES) has remarkable adaptive capacities to high pulmonary pressures (3), leading to a longer survival in these patien...
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Research Correspondence Source Type: research
Journal of Cardiac Surgery, EarlyView.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: IMAGES IN CARDIAC SURGERY Source Type: research
The outcome of second solid cancers following hematopoietic stem cell transplantation (HSCT) is strongly related to cancer type, with pancreatic and lung cancer being among those with the poorest outcome, according to European researchers.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
More News: Funding | Lung Transplant | Medical Devices | National Institute for Health Research (NIHR) | Respiratory Medicine